Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YAEL RACHEL ELFASSY

Allopathic & Osteopathic Physicians Pediatrics

NPI
1598081002
CMS profile
253025
Location
SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$31.57

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $31.57 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI PASTEUR INC. $31.57 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YAEL RACHEL ELFASSY

NPI 1598081002 · CMS profile ID 253025

Allopathic & Osteopathic Physicians / Pediatrics

SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $31.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI PASTEUR INC. $17.4208/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937307117 CMS
SANOFI PASTEUR INC. $14.1504/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937307105 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $31.57 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $908,633.80 124
PY2024 Principal investigator $942,634.71 86
PY2023 Recipient $511.38 1
PY2023 Principal investigator $550,439.29 47
PY2022 Principal investigator $196,273.44 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

124 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $822.38 12/15/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006679
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,200.00 12/05/2025 Non-covered Recipient Entity
Cenexel Iresearch, Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Manic Episodes or Mixed Manic Episodes in Individuals with Bipolar-I Disorder and Inadequate Response to Lithium, Valproate, or Lamotrigine No dispute reported 06/30/2026 1235998272
Principal investigator 1 ModernaTX, Inc. $7,250.00 12/04/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006641
Principal investigator 1 ModernaTX, Inc. $1,800.00 12/04/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006655
Principal investigator 1 Corium, LLC $4,265.55 11/25/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181950080
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,843.22 11/21/2025 Non-covered Recipient Entity
Cenexel Iresearch, Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Manic Episodes or Mixed Manic Episodes in Individuals with Bipolar-I Disorder and Inadequate Response to Lithium, Valproate, or Lamotrigine No dispute reported 06/30/2026 1235998270
Principal investigator 1 SANOFI PASTEUR INC. $2,177.56 11/19/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226103512
Principal investigator 1 ModernaTX, Inc. $1,000.00 11/14/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974837
Principal investigator 1 ModernaTX, Inc. $1,950.00 11/14/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974847
Principal investigator 1 ModernaTX, Inc. $500.00 11/05/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974851
Principal investigator 1 ModernaTX, Inc. $1,500.00 11/05/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974855
Principal investigator 1 Corium, LLC $1,495.95 10/30/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181950078
Principal investigator 1 ABBVIE INC. $1,755.00 10/22/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1202518057
Principal investigator 1 ABBVIE INC. $2,250.00 10/22/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1202518059
Principal investigator 1 ABBVIE INC. $3,250.00 10/22/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1202518171
Principal investigator 1 SANOFI PASTEUR INC. $10,207.00 10/16/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226103478
Principal investigator 1 SANOFI PASTEUR INC. $1,563.00 10/16/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226103482
Principal investigator 1 SANOFI PASTEUR INC. $500.00 10/16/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226103490
Principal investigator 1 SANOFI PASTEUR INC. $4,250.00 10/16/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226103494
Principal investigator 1 SANOFI PASTEUR INC. $2,500.00 10/16/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226103502
Principal investigator 1 SANOFI PASTEUR INC. $2,713.00 10/16/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226103507
Principal investigator 1 SANOFI PASTEUR INC. $1,087.63 09/10/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226103427
Principal investigator 1 ModernaTX, Inc. $750.00 08/28/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974839
Principal investigator 1 ModernaTX, Inc. $800.00 08/28/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974841
Principal investigator 1 ModernaTX, Inc. $1,900.00 08/28/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974859
Principal investigator 1 ModernaTX, Inc. $1,280.00 08/28/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974865
Principal investigator 1 ModernaTX, Inc. $39.52 08/28/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006637
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $250.00 08/27/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder No dispute reported 06/30/2026 1242358194
Principal investigator 1 Amgen Inc. $6,200.00 08/23/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246640145
Principal investigator 1 ABBVIE INC. $3,269.08 08/18/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202505029
Principal investigator 1 ABBVIE INC. $842.00 08/13/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202504473
Principal investigator 1 ABBVIE INC. $857.50 08/01/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202500860
Principal investigator 1 ABBVIE INC. $1,523.22 08/01/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202500862
Principal investigator 1 PFIZER INC. $475.00 07/26/2025 Non-covered Recipient Entity
CenExel iResearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228784678
Principal investigator 1 SANOFI PASTEUR INC. $1,165.05 07/25/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226103433
Principal investigator 1 Corium, LLC $2,582.03 07/10/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181950030
Principal investigator 1 ModernaTX, Inc. $1,892.70 07/09/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974843
Principal investigator 1 ModernaTX, Inc. $1,600.00 07/09/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974853
Principal investigator 1 ABBVIE INC. $1,145.31 07/03/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202496859
Principal investigator 1 ABBVIE INC. $722.42 07/03/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202496861
Principal investigator 1 ABBVIE INC. $489.62 07/03/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202496863
Principal investigator 1 ABBVIE INC. $649.62 07/03/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202496865
Principal investigator 1 ABBVIE INC. $649.62 07/03/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202496867
Principal investigator 1 ABBVIE INC. $682.12 07/03/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202496869
Principal investigator 1 ModernaTX, Inc. $100.00 07/02/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974833
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $12,769.36 07/01/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder No dispute reported 06/30/2026 1242352480
Principal investigator 1 Celgene Corporation $11,500.00 06/27/2025 Non-covered Recipient Entity
Cenexel Iresearch Atlanta
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1222305664
Principal investigator 1 Corium, LLC $3,407.03 06/26/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949984
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,821.72 06/24/2025 Non-covered Recipient Entity
Cenexel Iresearch, Llc
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1235998268
Principal investigator 1 ModernaTX, Inc. $14,741.12 06/18/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006629
Principal investigator 1 Corium, LLC $26,878.88 06/11/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949982
Principal investigator 1 ModernaTX, Inc. $4,999.28 05/28/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006617
Principal investigator 1 ModernaTX, Inc. $15,201.78 05/28/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006649
Principal investigator 1 Eli Lilly and Company $6.72 05/16/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187883376
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 05/16/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder No dispute reported 06/30/2026 1242347554
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $750.00 05/16/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder No dispute reported 06/30/2026 1242347556
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 05/16/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder No dispute reported 06/30/2026 1242347558
Principal investigator 1 SANOFI PASTEUR INC. $1,319.36 05/14/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226103421
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/09/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006625
Principal investigator 1 ModernaTX, Inc. $500.00 05/09/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006651
Principal investigator 1 Amgen Inc. $118.73 05/08/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) No dispute reported 06/30/2026 1246640143
Principal investigator 1 ModernaTX, Inc. $1,958.85 05/07/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974861
Principal investigator 1 ABBVIE INC. $75.00 04/28/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202479790
Principal investigator 1 ModernaTX, Inc. $6,303.44 04/28/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006653
Principal investigator 1 ModernaTX, Inc. $3,043.04 04/28/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006667
Principal investigator 1 ModernaTX, Inc. $921.32 04/28/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006675
Principal investigator 1 ABBVIE INC. $1,500.00 04/25/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202479540
Principal investigator 1 ABBVIE INC. $1,200.00 04/25/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202479552
Principal investigator 1 ABBVIE INC. $842.00 04/25/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202479556
Principal investigator 1 ABBVIE INC. $839.44 04/18/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202478122
Principal investigator 1 SANOFI PASTEUR INC. $979.63 04/16/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226103413
Principal investigator 1 ABBVIE INC. $1,829.55 04/05/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202474593
Principal investigator 1 ABBVIE INC. $2,894.75 04/05/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202474597
Principal investigator 1 ABBVIE INC. $2,959.21 04/05/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202474601
Principal investigator 1 ModernaTX, Inc. $1,500.00 04/04/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974835
Principal investigator 1 ModernaTX, Inc. $621.00 04/01/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974863
Principal investigator 1 ModernaTX, Inc. $6,086.08 03/24/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006643
Principal investigator 1 ModernaTX, Inc. $7,370.56 03/24/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006659
Principal investigator 1 ModernaTX, Inc. $5,730.40 03/24/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006669
Principal investigator 1 ABBVIE INC. $8,474.02 03/21/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202465471
Principal investigator 1 ModernaTX, Inc. $1,500.00 03/21/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974857
Principal investigator 1 ABBVIE INC. $2,587.37 03/19/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464893
Principal investigator 1 ABBVIE INC. $7,257.91 03/19/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464897
Principal investigator 1 SANOFI PASTEUR INC. $2,259.84 03/14/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226103403
Principal investigator 1 ModernaTX, Inc. $12,172.16 02/27/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006627
Principal investigator 1 ModernaTX, Inc. $6,639.36 02/27/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006645
Principal investigator 1 ModernaTX, Inc. $2,725.64 02/27/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006647
Principal investigator 1 ModernaTX, Inc. $1,068.28 02/27/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006663
Principal investigator 1 ModernaTX, Inc. $15,662.44 02/27/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006683
Principal investigator 1 Corium, LLC $16,276.96 02/20/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Efficacy and Safety Study w/ Azstarys in Children With ADHD No dispute reported 06/30/2026 1181949940
Principal investigator 1 Eli Lilly and Company $182,798.70 02/19/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187878943
Principal investigator 1 ModernaTX, Inc. $822.38 02/19/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006665
Principal investigator 1 SANOFI PASTEUR INC. $2,205.90 02/19/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226103396
Principal investigator 1 SANOFI PASTEUR INC. $2,058.75 02/18/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226103446
Principal investigator 1 ABBVIE INC. $9,000.00 02/12/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202450869
Principal investigator 1 ABBVIE INC. $3,650.00 02/05/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202446667
Principal investigator 1 Corium, LLC $1,495.95 02/05/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949920
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $10,500.00 02/05/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder No dispute reported 06/30/2026 1242330057
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,250.00 02/05/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder No dispute reported 06/30/2026 1242330059
Principal investigator 1 Eli Lilly and Company $81,021.00 02/04/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187878991
Principal investigator 1 Eli Lilly and Company $4,536.95 01/31/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883370
Principal investigator 1 Corium, LLC $1,495.95 01/29/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949918
Principal investigator 1 ModernaTX, Inc. $150.00 01/29/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974849
Principal investigator 1 ABBVIE INC. $3,270.29 01/28/2025 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202441736
Principal investigator 1 ModernaTX, Inc. $24,570.44 01/27/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006631
Principal investigator 1 ModernaTX, Inc. $6,975.28 01/27/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006657
Principal investigator 1 ModernaTX, Inc. $12,172.16 01/27/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006671
Principal investigator 1 ModernaTX, Inc. $1,381.98 01/27/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006673
Principal investigator 1 ModernaTX, Inc. $3,376.48 01/23/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006619
Principal investigator 1 ModernaTX, Inc. $57,238.44 01/23/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006623
Principal investigator 1 ModernaTX, Inc. $11,055.84 01/23/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006635
Principal investigator 1 ModernaTX, Inc. $7,607.60 01/23/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006639
Principal investigator 1 ModernaTX, Inc. $29,911.84 01/23/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006661
Principal investigator 1 ModernaTX, Inc. $6,876.48 01/23/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006677
Principal investigator 1 ModernaTX, Inc. $3,906.30 01/23/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006681
Principal investigator 1 ModernaTX, Inc. $310.50 01/22/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252974845
Principal investigator 1 ModernaTX, Inc. $5,000.00 01/22/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006621
Principal investigator 1 ModernaTX, Inc. $1,500.00 01/22/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006633
Principal investigator 1 SANOFI PASTEUR INC. $75,513.60 01/21/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226103452
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,534.00 01/15/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH ATLANTA
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185547187
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 01/08/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226103391
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 01/06/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226103440
Principal investigator 1 SANOFI PASTEUR INC. $2,909.66 01/03/2025 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226103407
Principal investigator 1 ABBVIE INC. $1,500.00 01/02/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
M21-465 - Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1202436098